Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)
|ClinicalTrials.gov Identifier: NCT03591757|
Recruitment Status : Completed
First Posted : July 19, 2018
Last Update Posted : June 14, 2019
The purpose of this study is to determine whether Tolcapone crosses from the blood stream into the fluid around the brain and stabilizes the protein that makes leptomeningeal amyloid. Tolcapone is a commercially available generic drug that treats Parkinson's disease.
The Investigator plans to evaluate Tolcapone as a treatment for ATTR (Transthyretin Amyloidosis), a rare genetic disease often causing death within 5-15 years after diagnosis. ATTR is characterized by deposition of misfolded protein known as amyloid, in one or more organ systems (including the peripheral and autonomic nervous systems, the heart, the brain and the eyes). The age at which symptoms begin to develop varies widely ranging between 20 to 70 years old. ATTR is progressive, and some variants can have a fatal outcome within a few years of presentation. Treatment options include supportive and symptomatic care that may slow or stop progressive decline in functional state but do not alter the pathological process. Liver transplant can be performed in selected patients but is limited by organ supply, requires lifelong immunosuppression, and may be complicated by progressive heart and nerve amyloid deposition. Importantly, liver transplant does not alter the natural course of central nervous system amyloid disease. To date, no treatment for ATTR penetrates the CNS.
At present there is no FDA approved treatment for ATTR amyloidosis in the US. In Europe, Tafamidis has been approved for treatment of stage 1 ATTR-polyneuropathy since 2012. Tafamidis and Tolcapone bind to the thyroxine binding site of TTR (with different drug-transthyretin interactions) and in so doing stabilizes the tetrameric form of TTR, preventing dissociation and amyloid fibril formation The preclinical and clinical data from a variety of experimental systems support the therapeutic activity of TOLCAPONE in TTR mediated disease.
|Condition or disease||Intervention/treatment||Phase|
|Transthyretin Amyloidosis Amyloidosis, Leptomeningeal, Transthyretin-Related||Drug: Tolcapone||Early Phase 1|
This study is designed as a clinical proof-of-concept evaluating whether TOLCAPONE is capable of stabilizing tetrameric TTR (Transthyretin) in the plasma and CSF of symptomatic or asymptomatic patients with leptomeningeal ATTR. Additionally the study will determine the plasma and CSF concentrations of TOLCAPONE needed to induce maximal stabilization of TTR across different TTR variants (TTR mutations).
The study will be carried out in two different populations of subjects, defined by the TTR variant expressed:
- Mutant TTR (up to 10 subjects): symptomatic leptomeningeal TTR patient with any documented leptomeningeal mutations in the TTR gene.
- Mutant TTR (remaining subjects up to 10): asymptomatic leptomeningeal TTR patient with any documented leptomeningeal mutation in the TTR gene.
TTR tetramers stability in plasma and CSF samples will be determined by urea-induced denaturation methodology.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Patients with hATTR mutations conferring leptomeningeal amyloidosis.|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Investigator Study to Evaluate the Short-term (4 Weeks) Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) With and Without CNS Manifestations|
|Actual Study Start Date :||October 30, 2018|
|Actual Primary Completion Date :||April 26, 2019|
|Actual Study Completion Date :||April 26, 2019|
Tolcapone will be administered to assess the short-term (4 weeks) effects on plasma and CSF TTR tetramer stability in subjects with TTR CNS Amyloidosis. Tolcapone is currently licensed for the treatment of Parkinson's disease in combination with levodopa/carbidopa. It is an immediate release product and is currently used at either 100 mg or 200 mg three times a day during waking hours. During this trial, participants will be taking 100mg for 14 days, and then 200mg for 14 days.
Tolcapone will be administered at 300 mg/day (100mg TID) orally to participants for 14 days and then 600 mg/day (200 mg TID) orally to participants for 14 days (approximately 5 hours apart). Participants will initiate 200mg TID after blood collection on Day 14.
Other Name: Tasmar
- Change in plasma TTR stabilization [ Time Frame: pre-treatment (Day 0) and Day 28 ]TTR stabilization will be measured in plasma samples from each participant before the first dose of study drug and 2 hours after the last 100 mg study drug dose.
- Change in CSF TTR stabilization [ Time Frame: pre-treatment (Day 0) and Day 28 ]TTR stabilization will be measured in CSF samples obtained from each participant before the first dose of study drug and 2 hours after the last 200 mg dose.
- Changes in plasma TTR stabilization [ Time Frame: pre-treatment (Day 0) and Day 14 ]TTR stabilization will be measured in plasma samples from each participant before the first dose of study drug and 2 hours after the day 14 study drug dose.
- Changes in plasma TTR stabilization [ Time Frame: Day 14 and Day 28 ]TTR stabilization will be measured in plasma samples from each participant 2 hours after the day 14 study drug dose.and 2 hours after the 28 day study dose
- Tolcapone Concentration in CSF [ Time Frame: Day 14 ]Tolcapone concentration will be measured in CSF at Day 14 prior to starting 200mg TID dosing.
- Tolcapone Concentration in CSF [ Time Frame: Day 28 ]Tolcapone concentration will be measured in CSF at Day 28 2 hours after dose
- Tolcapone Concentration in Serum [ Time Frame: Day 14 ]Tolcapone concentration will be measured in serum at Day 14 prior to initiating 200 mg TID dosing
- Tolcapone Concentration in Serum [ Time Frame: Day 28 ]Tolcapone concentration will be measured in serum at Day 28 2 hours after last dose
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03591757
|United States, Massachusetts|
|Amyloidosis Center, Boston Medical Center|
|Boston, Massachusetts, United States, 02118|
|Principal Investigator:||John L Berk, MD||The Amyloidosis Center, BUSM|